By Fineline Cube 
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced robust 2025 financial results, with RMB 15.028 billion (USD 2.175 billion) in revenue, up 22.6% year-over-year, and net profit of RMB 5.555 billion (USD 800 million), rising 27.1% YOY. The company’s innovative and partnered products—now 82.2% of total sales—sustained over 30% growth for the third consecutive period, while oncology therapies accounted for two-thirds of revenue. Hansoh also secured three major out-licensing agreements with Regeneron, Roche, and Glenmark, totaling USD 4.54 billion, pushing its three-year cumulative licensing value past USD 9 billion.
Financial Highlights (2025)
| Metric | Amount (RMB) | Amount (USD) | YOY Change |
|---|---|---|---|
| Total Revenue | ¥15.028B | $2.175B | ↑22.6% |
| Net Profit | ¥5.555B | $800M | ↑27.1% |
| R&D Expenditure | ¥3.358B | $486M | ↑24.3% |
| Innovative + Partnered Revenue | ¥12.354B | $1.8B | ↑30.4% (82.2% of total) |
Strong margin expansion reflects a strategic shift from generics to high-value innovative medicines.
Revenue by Therapeutic Area
| Therapeutic Area | Revenue (RMB) | Revenue (USD) | Share of Total |
|---|---|---|---|
| Oncology | ¥9.974B | $1.44B | 66.4% |
| Metabolism & Other | ¥2.158B | $312M | 14.3% |
| Anti-infectives | ¥1.586B | $229M | 10.6% |
| CNS | ¥1.310B | $189M | 8.7% |
Oncology remains the dominant growth pillar, anchored by Ameile (almonertinib), Hansoh’s flagship EGFR-TKI.
Global Expansion Milestones
- Ameile Launch: Successfully commercialized in the UK and EU in 2025—the first China-originated EGFR-TKI approved and marketed overseas.
- Licensing Agreements:
- Regeneron: Undisclosed oncology asset
- Roche: CNS pipeline candidate
- Glenmark: Metabolic disorder program
- Cumulative Out-Licensing Value (2023–2025): >USD 9 billion, signaling strong international validation of Hansoh’s R&D engine.
Strategic Outlook
Hansoh’s transformation into an innovation-led global biopharma is now evident:
R&D intensity: 22.3% of revenue invested in R&D
Asset monetization: Licensing deals de-risk development and fund next-gen candidates
Geographic diversification: European approval opens gateway to broader Western markets
The company aims to further expand its global clinical footprint and accelerate IND filings in the U.S. and EU for its proprietary pipeline.
Forward‑Looking Statements
This brief contains forward-looking statements regarding commercial performance, regulatory approvals, and partnership execution. Actual results may vary due to market competition, reimbursement dynamics, and clinical trial outcomes.-Fineline Info & Tech